Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction

Jian-Jun Zhang, MB, Xin Liu, MB*

Abstract

Background: The standardization for the clinical use of drug therapy for cerebral infarction (CI) has not yet determined in some aspects. In this paper, we discussed the efficacies of different drug therapies (aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, clopidogrel, warfarin, and ticlopidine) for CI.

Methods: We searched databases of PubMed and Cochrane Library from the inception to April, 2017, randomized controlled trials (RCTs) met the inclusion and exclusion criteria were enrolled in this study. The network meta-analysis integrated evidences of direct and indirect comparisons to assess odd ratios (OR) and surface under the cumulative ranking curves (SUCRA) value.

Results: Thirteen eligible RCTs including 7 drug therapies were included into this network meta-analysis. The network meta-analysis results showed that CI patients who received aspirin plus dipyridamole presented lower mortality when compared with those received aspirin plus clopidogrel (OR = 0.46, 95% CI = 0.18–0.99), indicating aspirin plus dipyridamole therapy had better efficacy for CI. As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies. Besides, SUCRA values demonstrated that in the 7 drug therapies, aspirin plus dipyridamole therapy was more effective than others (mortality: 80.67%; ICH: 76.6%; AE rate: 90.2%).

Conclusions: Our findings revealed that aspirin plus dipyridamole therapy might be the optimum one for patients with CI, which could help to improve the survival of CI patients.

Abbreviations: ADP = adenosine diphosphate, CI = cerebral infarction, COX-1 = cyclooxygenase-1, ICH = intracranial hemorrhage, OR = odd ratios, RCTs = randomized controlled trials, SUCRA = surface under the cumulative ranking curves.

Keywords: cerebral infarction, drug therapy, efficacy, network meta-analysis, randomized controlled trials

1. Introduction

Cerebral infarction (CI), an ischemic stroke, is a frequent and serious complication of cerebral vascular disease, characterized by thrombosis, embolism, or systemic hemodynamic hypotension.[1,2] It is accepted that CI is caused by atherosclerosis of large and small arteries, which results from an atherothrombotic or embolic blockage of the blood vessels supplying blood to the brain.[2] Among stroke patients, 80% suffer from CI and 20% suffer from cerebral hemorrhage consequently. In addition, due to the rising number of patients, CI gradually is becoming a public health concern and is widely regarded as the first cause of disability and mortality.[3,4] Generally, CI is known to be a multifactorial disease induced by complex interactions between environmental and genetic factors.[3] Many intrinsic and extrinsic risk factors for CI have been established, such as diabetes, tobacco smoking, hypercholesterolemia, high blood pressure, and obesity.[2] Currently, drug therapy is the main treatment for CI, including thrombolytic agents, anti-platelet aggregation drugs, anti-fibrinogen drug, anticoagulation, neuro-protective drugs, and other commonly used drugs. Since the anti-platelet aggregation drugs can prevent thrombosis, hence they have beneficial effects on prevention and treatment of CI.[6–9]

A previous study has shown that the application of anti-platelet aggregation drugs can reduce 11% to 15% of CI recurrence rate.[10] At present, anti-platelet aggregation drugs include cyclooxygenase inhibitors (aspirin), ADP receptor antagonists (prasugrel, clopidogrel, ticlopidine), phosphodiesterase inhibitors (cilostazol, dipyridamole), platelet GP IIb/IIIa antagonists (abciximab), etc.[11,12] Due to its protective abilities which result from a variety of different mechanisms, anti-platelet aggregation is being widely used to treat CI in recent years.[10] And these
widely used drugs had different efficacies in the treatment of CI. For example, a previous study showed that aspirin plus clopidogrel could significantly decrease vascular death compared with warfarin while non-significantly reduce the rate of recurrent stroke (including intracerebral hemorrhage), myocardial infarction, peripheral embolism in the treatment of ischemic stroke, and aortic arch plaques.\(^{13}\) Besides, it was found that aspirin combined with dipyridamole had better efficacy than aspirin alone in the treatment of CI.\(^{14}\) However, some findings suggested that warfarin in combination with aspirin had no additional benefits while increased the risk of adverse effects in comparison to aspirin alone.\(^{15}\) Therefore, when different effects of anti-platelet aggregation drugs were compared, it suggested clinical guidelines for drug treatment of CI.

Meta-analysis can compare the efficacy and safety of multiple interventions for the same disease, and select the best one based on interventions.\(^{16}\) Therefore, this study is designed to compare the efficacy of 7 drug therapies in the treatment of CI and provide more evidences for clinical application.

### 2. Materials and methods

#### 2.1. Ethics statement

Our study is a meta-analysis and the ethics statement is not applicable.

#### 2.2. Retrieval strategy

English databases, including PubMed and Cochrane library were used to retrieve relevant references in combination of manual retrieval. Retrieval range was from the establishment of the database up to January 2017. The search terms included drug therapy, aspirin, and cerebral infarction based on the combination of free words and key words.

#### 2.3. Inclusion and exclusion criteria

Eligibility criteria: study types: randomized controlled studies; interventions: aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol, warfarin, and ticlopidine; study subjects: CI patients aged between 44 and 86 years; outcomes: intracranial hemorrhage (ICH), mortality, stroke recurrence, and adverse event rate (AE). Exclusion criteria: patients with severe artery occlusive diseases; patients allergic to clopidogrel, aspirin, or anticoagulant therapy; patients with advanced malignant tumor or dysfunction in blood, liver, and kidney; patients with severe hypertension; incomplete data; non-randomized controlled trials; overlap literatures; conference report, system evaluation, or abstract articles; non-English literatures.

#### 2.4. Data extraction and quality assessment

Two researchers extracted the included literature data independently, according to the unified data collection form. Disputations during the process reached consensus through discussions of several investigators. The evaluation of randomized controlled trials was conducted by 2 or more researchers using Cochrane risk of bias assessment tool,\(^{17}\) which included 6 domains such as random assignment, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting, and other sources of bias. The assessment of “yes,” “no,” or “unclear” was assigned to each domain for respective designation of a low, high, or unclear risk of bias. If “unclear” or “no” judgment was rated in any domain, the study was deemed as presenting a low risk of bias. If over 4 domains were assessed as “unclear” or “no,” a moderate risk of bias was designated to the study.\(^{18}\) Review Manager 5 conducted both quality evaluation and publication bias investigation (RevMan 5.2.3, Cochrane Collaboration, Oxford, UK).

#### 2.5. Statistical analysis

Firstly, traditional pairwise meta-analyses were conducted for the studies with direct comparison of different treatment arms. Both odd ratios (ORs) and 95% credible intervals (CIs) estimations were pooled and reported. I-square test and Chi-square test were applied to test heterogeneity among different studies.\(^{19}\) Secondly, network diagrams were performed by the software R (V.3.2.1) package gmeta (V.0.6), and each node represented a single intervention, the size of node represented the sample size and the lines between the nodes represented the number of eligible studies. Thirdly, different interventions were compared with each other via Bayesian network meta-analyses, which were performed on the basis of non-informative priors for the purpose of effect sizes and precision. After 4 chains and a burn-in phase of 20,000 simulations, examinations confirmed convergence and lack of auto relation, hence conclusively producing direct probability statements deriving from another 50,000 simulation phase.\(^{20}\) In order to facilitate the process of the interpretation of ORs, the probability of each intervention was computed as the safest or most satisfactory cure method of Bayesian approach based on probability values, and thus summarized as surface under the cumulative ranking curve (SUCRA). A larger SUCRA value symbolized a better rank of intervention.\(^{21,22}\) All calculations were computed by R (V.3.2.1) package gmeta (V.0.6), and accompanied by Markov Chain Monte Carlo engine Open BUGS (V.3.4.0).

### 3. Results

#### 3.1. In total, 16,771 participants from 12 two-arm RCTs and 1 three-arm RCT are selected in this study

Initially, 1325 records were searched and 775 remained after exclusion of 10 duplicates, 151 letters or reviews, 226 non-human studies, and 163 non-English literatures. The full-text screening ruled out 198 non-cohort studies, 558 irrelevant trials, 6 with incomplete data, and 13 completely randomized controlled trials were comprised in this network meta-analysis\(^{23-35}\) (Supplementary Fig 1, http://links.lww.com/MD/C160). A total of 16,771 CI patients were recorded in this study, with the most preferable treatment being aspirin and the least preferred being aspirin plus dipyridamole. The eligible studies were published between 2001 and 2017, of which subjects in 8 trials were Caucasians and the remainder was Asians. Twelve trials belonged to two-arm trials and 1 was in the category of a three-arm trial. The baseline characteristics are outlined in Table 1 and the Cochrane bias evaluation is shown in Fig. 1.

#### 3.2. Results from pairwise meta-analysis of 7 drug therapies in the treatment of CI in terms of mortality rate, stroke recurrence rate, and AE rate

Pairwise comparisons upon 7 drug therapies revealed a lower mortality rate in patients who preferred aspirin and aspirin plus dipyridamole treatment than patients selecting treatment of...
aspirin plus clopidogrel (OR = 0.60, 95%CI = 0.40–0.90, OR = 0.31, 95%CI = 0.16–0.62, respectively). Aspirin had higher stroke recurrence rate as compared with cilostazol (OR = 1.10, 95%CI = 0.60–2.16, respectively). And aspirin had higher mortality rate than aspirin plus clopidogrel (OR = 1.99, 95%CI = 0.18–0.99), suggesting that aspirin plus dipyridamole had better efficacy than aspirin plus clopidogrel in the treatment of CI (Table 3 and Fig. 3). ICH, stroke recurrence, and AE rate, all did not deliver any significant difference among the 7 drug therapies (Supplementary Fig. 2 and Supplementary Table 1, http://links.lww.com/MD/C160).

3.3. Network evidence results showing more patients receive aspirin and less patients receive aspirin plus clopidogrel among 7 drug therapies in the treatment of CI

This study included 7 drug therapies: aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol, warfarin, and ticlopidine. Among these drug therapies, the number of patients receiving aspirin was the highest, and aspirin plus clopidogrel was the least desired treatment (Fig. 2).

3.4. Results from network meta-analysis suggesting aspirin plus dipyridamole have better efficacy among 7 drug therapies in the treatment of CI

Between the 7 drug therapies, aspirin plus dipyridamole had lower mortality rate than aspirin plus clopidogrel (OR = 0.46, 95%CI = 0.18–0.99), suggesting that aspirin plus dipyridamole had better efficacy than aspirin plus clopidogrel in the treatment of CI (Table 3 and Fig. 3). ICH, stroke recurrence, and AE rate, all did not deliver any significant difference among the 7 drug therapies (Supplementary Fig. 2–4 and Supplementary Table 1, http://links.lww.com/MD/C160).

3.5. SUCRA values results indicating aspirin plus dipyridamole ranked the highest in terms of mortality, ICH, and AE rate among 7 drug therapies in the treatment of CI

Figure 4 implied the rank probability of the treatment effect among all the therapies. The SUCRA value indicated that aspirin plus dipyridamole ranked the highest in terms of mortality, ICH and AE rate (mortality: 80.67%; ICH: 76.6%; AE rate: 90.2%), while concerning stroke recurrence. Cilostazol ranked the first
Table 2
Estimated OR and 95% CI from pairwise meta-analysis for efficacy events in cerebral infarction patients.

| Included studies | Comparisons | Treatment1 | Treatment2 | OR (95%CI) | \( I^2 \) | \( P_a \) |
|------------------|-------------|------------|------------|-----------|----------|--------|
| Mortality        | Four studies A vs B | 563/5263 | 179/2729 | 1.24 (0.79–1.95) | 68.7% | 0.022 |
|                  | Three studies A vs F | 135/2486 | 124/2496 | 1.10 (0.86–1.42) | 0.00% | 0.918 |
|                  | Two studies A vs C | 403/3051 | 32/181 | 0.60 (0.40–0.90) | 0.00% | 0.804 |
|                  | Three studies A vs E | 16/1593 | 15/1596 | 1.06 (0.52–2.17) | 0.00% | 0.858 |
|                  | One study A vs G | 40/907 | 45/902 | 0.88 (0.57–1.36) | NA | NA |
|                  | One study B vs C | 13/175 | 31/151 | 0.31 (0.16–0.62) | NA | NA |
| ICH              | Two studies A vs E | 3/258 | 2/259 | 1.50 (0.24–9.34) | 0.00% | 0.710 |
|                  | One study A vs F | 58/280 | 51/289 | 1.22 (0.80–1.85) | NA | NA |
|                  | One study B vs C | 4/175 | 6/151 | 0.57 (0.16–2.04) | NA | NA |
|                  | Four studies A vs B | 116/5563 | 47/2729 | 1.02 (0.68–1.53) | 42.8% | 0.155 |
|                  | Two studies A vs C | 74/3051 | 7/181 | 0.62 (0.27–1.39) | 0.00% | 0.814 |
| Stroke recurrence| Three studies A vs B | 201/2547 | 182/2554 | 1.08 (0.77–1.51) | 55.9% | 0.104 |
|                  | One study A vs C | 2/35 | 1/30 | 1.76 (0.15–20.40) | NA | NA |
|                  | One study A vs D | 1/28 | 1/28 | 1.00 (0.06–16.82) | NA | NA |
|                  | One study A vs G | 16/907 | 107/902 | 0.78 (0.58–1.05) | NA | NA |
|                  | Three studies A vs E | 125/1593 | 88/1596 | 1.46 (1.10–1.94) | 0.00% | 0.653 |
|                  | Three studies A vs F | 303/2486 | 347/2496 | 0.88 (0.70–1.11) | 44.0% | 0.168 |
| AE rate          | One study A vs B | 116/405 | 128/404 | 0.86 (0.64–1.17) | 0.00% | 0.406 |
|                  | One study A vs C | 105/248 | 49/247 | 2.97 (1.99–4.43) | NA | NA |
|                  | Three studies A vs E | 617/1559 | 661/1562 | 0.94 (0.82–1.07) | 0.00% | 0.764 |
|                  | One study A vs G | 194/210 | 177/210 | 2.26 (1.20–4.25) | NA | NA |

\( A = \text{aspirin}, \ AE = \text{adverse event}, \ B = \text{aspirin + dipyridamole}, \ C = \text{aspirin + clopidogrel}, \ CI = \text{confidence intervals}, \ D = \text{aspirin + warfarin}, \ E = \text{cilostazol}, \ F = \text{warfarin}, \ G = \text{ticlopidine}, \ ICH = \text{intracranial hemorrhage}, \ NA = \text{not available}, \ OR = \text{odd ratios} \)

Figure 2. Network evidence graphs of mortality, ICH, stroke recurrence, and AE rate among 7 drug therapies in the treatment of CI. (Note: AE = adverse events, CI = confidence interval, ICH = intracranial hemorrhage).
(80.0%) and ticlopidine ranked the lowest (33.71%), which revealed that aspirin plus dipyridamole may be the best treatment regimen for CI patients, while the effect of aspirin plus clopidogrel on IC was the worst.

4. Discussion

This network meta-analysis evaluated the relative efficacy of 7 drug therapies (aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol, warfarin, and ticlopidine) on CI. According to the results, aspirin plus dipyridamole appeared to be the most effective treatment, while aspirin plus clopidogrel exhibited the poorest efficacy, correspondingly.

The study demonstrated that the combination of aspirin and dipyridamole was relatively the most effective in comparison to the other 6 drug therapies for CI. It is known that aspirin can achieve remarkable antiplatelet effects through acetylation of serine residue 530 of cyclooxygenase-1 (COX-1), causing irreversible inactivation of COX-1 and blocking the transformation of arachidonic acid into thromboxane A2 (a powerful platelet agonist and vasoconstrictor). Thus, aspirin can reduce risks of stroke and coronary artery disease.[36,37] As the previous study indicated, dipyridamole was reported to reduce risk of vascular event after ischemic stroke similarly to aspirin.[38] The combination of aspirin and dipyridamole played a more effectual role than aspirin monotherapy in ischemic stroke of presumed arterial origin,[39] which indicated that aspirin and dipyridamole may exhibit synergistic action during the process. Also, aspirin plus extended-release dipyridamole presented a relative decreased risk of 22% in comparison to only aspirin.[32]

### Table 3

Odds ratios and 95% confidence intervals of six treatment modalities of mortality.

|        | Odd Ratio   | 95% CI        |
|--------|-------------|---------------|
| Aspirin| 0.83 (0.48, 1.26) | 1.79 (0.82, 4.11) |
|        | 1.20 (0.80, 2.07) | 0.91 (0.35, 2.39) |
|        | 0.56 (0.24, 1.22) | 1.10 (0.58, 2.39) |
|        | 1.10 (0.65, 1.81) | 1.37 (0.54, 3.96) |
|        | 0.88 (0.46, 2.15) | 0.80 (0.30, 2.58) |

Comparison: A vs B
Odds Ratio (95% CI) 1.20 (0.80, 2.07)

Comparison: A vs C
Odds Ratio (95% CI) 0.56 (0.25, 1.22)

Comparison: A vs D
Odds Ratio (95% CI) 1.10 (0.42, 2.85)

Comparison: A vs E
Odds Ratio (95% CI) 1.10 (0.65, 1.81)

Comparison: A vs F
Odds Ratio (95% CI) 0.88 (0.36, 2.15)

Comparison: B vs C
Odds Ratio (95% CI) 0.46 (0.18, 0.99)

Comparison: B vs D
Odds Ratio (95% CI) 0.90 (0.30, 2.58)

Comparison: B vs E
Odds Ratio (95% CI) 0.73 (0.29, 2.19)

Comparison: B vs F
Odds Ratio (95% CI) 0.73 (0.29, 2.19)

Comparison: C vs D
Odds Ratio (95% CI) 0.50 (0.14, 1.68)

Comparison: C vs E
Odds Ratio (95% CI) 0.50 (0.14, 1.68)

Comparison: C vs F
Odds Ratio (95% CI) 0.50 (0.14, 1.68)

Comparison: D vs E
Odds Ratio (95% CI) 1.00 (0.34, 3.96)

Comparison: D vs F
Odds Ratio (95% CI) 1.00 (0.34, 3.96)

Comparison: E vs F
Odds Ratio (95% CI) 1.00 (0.34, 3.96)

Table 3 Odds ratios and 95% confidence intervals below the treatments should be read from row to column while above the treatments should be read from column to row.

Figure 3. Relative relationship forest plots of mortality among (A) aspirin, (B) aspirin plus dipyridamole, (C) aspirin plus clopidogrel, (D) cilostazol, (E) warfarin, and (F) ticlopidine therapies in the treatment of CI. CI = confidence interval.
was found that warfarin plus aspirin had superiority of reducing the risk of infarction and ischemic stroke while could lead to a higher risk of bleeding.[40] However, Li et al.[41] found that aspirin plus dipyridamole therapy was efficacious in decreasing the recurrence of ischemic stroke without significant bleeding complication, which showed that aspirin plus dipyridamole was superior to warfarin plus aspirin treatment. In addition, aspirin plus dipyridamole had similar effects on preventing recurrent stroke when compared with clopidogrel.[42]

Additionally, our study also revealed that the combination of aspirin and clopidogrel was deemed as relatively the worst treatment method for CI. Clopidogrel is a derivative of thienopyridine that can inhibit platelet aggregation by selectively and irreversibly interdicting the adenosine diphosphate (ADP) receptor-P2Y12 on platelets, thus improving coronary syndromes.[43] A previous study revealed that clopidogrel was superior to aspirin alone in reducing the risk of ischemic stroke.[44] However, the combination of clopidogrel with aspirin failed to be more effective than clopidogrel monotherapy and instigated higher incidence of bleeding.[45] Bhatt et al.[46] further proved this phenomenon by suggesting that the two-step activation process of clopidogrel involved a series of cytochrome P450 enzyme metabolism which was susceptible to drug–drug interactions.[47] It was conjectured that antagonistic action existed between aspirin and clopidogrel. Aspirin and clopidogrel resistance was recognized in the prevention and treatment of coronary artery disease.[37,48]

Besides, as compared with the combination of aspirin and a thienopyridine (ticlopidine or clopidogrel), aspirin alone was reported to be safer and more effective in the prevention of stent thrombosis after optimal intracoronary implantation of the CarboStent.[49] A previous study also revealed that anticoagulation with warfarin may have better efficacy than aspirin plus clopidogrel as thromboprophylaxis in atrial fibrillation since aspirin plus clopidogrel could not decrease plasma indices of thrombogenesis and platelet activation.[50]

Network meta-analysis had some major advantages over traditional meta-analysis. It was not only a potent tool to integrate existing treatments for one clinical disease, but also served as an updated supplement to clinical guidelines and predicted future research needs.[51] However, there were some

Figure 4. The SUCRA diagrams in terms of mortality, ICH, stroke recurrence, and AE rate among 7 drug therapies in the treatment of CI. (Note: AE = adverse events, CI = confidence interval, ICH = intracranial hemorrhage, SUCRA = surface under the cumulative ranking curves).
limitations in this study. Firstly, this study was assessing outcomes only in European, American, and Asian population. Secondly, only 13 studies were enrolled in this meta-analysis and the number of included studies was relatively small with limited data and information. Therefore, it is hoped that these limitations will be improved in the future studies.

In summary, this study integrated and compared the efficacy of aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol, warfarin, and ticlopidine in the treatment of CI. The combination of aspirin plus dipyridamole treatment could achieve the greatest efficacy in comparison with other drug therapies, providing a significant guidance for the clinical treatment of CI.

Author contribution

Conceptualization: X. Liu.
Data curation: X. Liu.
Resources: J.-J. Zhang.
Supervision: J.-J. Zhang.
Writing – original draft: J.-J. Zhang.
Writing – review & editing: X. Liu.

Acknowledgment

The authors would like to send their sincere gratitude to those reviewers for their constructive comments.

References

[1] Gao HH, Gao LB, Wen JM. Correlations of MCP-1-2518A→G polymorphism and serum levels with cerebral infarction risk: a meta-analysis. DNA Cell Biol 2014;33:322–30.
[2] O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112–23.
[3] Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011;42:2351–5.
[4] Sen S, Rabbinstein AA, Ellkind MS, et al. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis 2012;33:209–18.
[5] Shimizu M, Yoshimura S, Takizawa S, et al. Effect of single nucleotide polymorphisms of the prostacyclin receptor gene on platelet activation in Japanese healthy subjects and patients with cerebral infarction. J Clin Neurosci 2013;20:831–6.
[6] Wang YX, Chen Y, Zhang CH, et al. Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction. Eur Rev Med Pharmacol Sci 2015;19:1009–12.
[7] Sugiyama N, Matsuda S, Shimizu M, et al. [Recent idiopathic cerebral infarction in a 3-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs]. No To Hattatsu 2009;41:47–51.
[8] Halinen M. [Assessment of risk of cerebral infarction and benefit of anticoagulant therapy in a patient with atrial fibrillation]. Duodecim 2014;130:47–53.
[9] Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–68.
[10] Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010;41:288–94.
[11] Shimizu M, Yoshimura S, Takizawa S, et al. Effect of single nucleotide polymorphisms of the prostacyclin receptor gene on platelet activation in Japanese healthy subjects and patients with cerebral infarction. J Clin Neurosci 2013;20:831–6.
[12] Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl):630S–69S.
[13] Amarenco P, Davis S, Jones EF, et al. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014;45:1248–57.
[14] Flynn RW, MacDonald TM, Murray GD, et al. Persistence, adherence and outcomes with antithrombotic regimens following cerebral infarction in the Tayside stroke Cohort. Cerebrovasc Dis 2012;33:190–7.
[15] Jeddy AS, Gleason RL. Aspirin and warfarin versus aspirin monotherapy after myocardial infarction. Ann Pharmacother 2003;37:1502–5.
[16] Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not pre-diagnosis improves established colorectal cancer survival: a meta-analysis. Gut 2015;64:1419–25.
[17] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[18] Chung JH, Lee SW. Assessing the quality of randomized controlled urological trials conducted by Korean medical institutions. Korean J Urol 2013;54:289–96.
[19] Shen LX, Li YL, Ning GZ, et al. Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review. PLoS One 2015;10:e0123153.
[20] Tu YK, Needleman J, Chambrome L, et al. A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. J Clin Periodontol 2012;39:303–14.
[21] Chaimani A, Higgins JP, Madhavi D, et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76634.
[22] Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analyses: an overview and tutorial. J Clin Epidemiol 2011;64:163–71.
[23] Lai YJ, Zhao Y, Chen C, et al. Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. Int J Stroke 2014;9(Suppl):127–32.
[24] Al-Atassi T, Lam K, Forgie M, et al. Cerebral microembolization after prosthodontic aortic valve replacement: comparison of warfarin plus aspirin versus aspirin only. Circulation 2012;126(Suppl):S259–44.
[25] Uchiyama S, Ikeda Y, Urano Y, et al. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. Cerebrovasc Dis 2011;31:601–13.
[26] Lee YS, Rae HJ, Kang DW, et al. Cilostazol in Acute Ischemic Stroke Treatment (CAST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011;32:65–71.
[27] Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–68.
[28] Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010;41:288–94.
[29] Xiao J, Xu E, Lin QY, et al. Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Neurosci Bull 2009;25:383–90.
[30] Halbes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arteriolar origin (ESPRT): a randomised controlled trial. Lancet Neurol 2007;6:115–24.
[31] Sacco RL, Prabhakaran S, Thompson JL, et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin–Aspirin Recurrent Stroke Study. Cerebrovasc Dis 2006;22:4–12.
[32] Group ES, Halbes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arteriolar origin (ESPRT): randomised controlled trial. Lancet 2006;367:1665–73.
[33] Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–16.
[34] Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947–57.
[35] Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–51.
[36] Fitzgerald DJ, Marce A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007;114–20.
[37] Gasparian AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008;51:1829–43.
[38] Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647–52.
[39] Halkes PH, Gray LJ, Bath PM, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 2008;79:1218–23.
[40] Aronow WS. Warfarin aspirin, or both after myocardial infarction. N Engl J Med 2003;348:256–7. author reply 56–7.
[41] Li X, Zhou G, Zhou X, et al. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci 2013;332:92–6.
[42] Is aspirin plus dipyridamole as effective as clopidogrel for preventing recurrent stroke? J Fam Pract 2008;57:781.
[43] Burdge JJ, Hartman JF, Wright ML. A study of HVPC as an adjunctive therapy in limb salvage for chronic diabetic wounds of the lower extremity. Ostomy Wound Manage 2009;55:30–8.
[44] Weber R, Weimar C, Diener HC. Antiplatelet agents in stroke prevention: acute and long-term treatment strategies. Hamostaseologie 2009;29:326–33.
[45] Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–7.
[46] Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17.
[47] Gilard M, Arnaud B, Cornely JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLoidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256–60.
[48] De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008;100:196–203.
[49] Bartorelli AL, Tamburino C, Trabattoni D, et al. Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent. Am J Cardiol 2007;99:1062–6.
[50] Kamath S, Blann AD, Chin BS, et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002;40:484–90.
[51] Knottnerus BJ, Gregoryan L, Geerlings SE, et al. Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials. Fam Pract 2012;29:659–70.